For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place ...

The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” executives explained to ...

Roche (OTCQX:RHHBY) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Genentech’s newly approved multiple sclerosis (MS) injection takes about 10 minutes to administer, dramatically reducing the ...

Following the announcement of a large layoff round in April and a major restructuring initiative unveiled earlier this month, Genentech is sending more jobs to the chopping block. The Roche ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

Genentech, a drugmaker based in South San Francisco, is laying off 93 more local workers just months after a 436-worker cut. The company, which is owned by Swiss pharmaceutical giant Roche ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir marboxil), an antiviral, ...